Regulatory Approvals

FDA Approves Frontline Sevabertinib for HER2-Mutant Advanced NSCLC Patients

By

Regulatory Approvals — FDA Approves Frontline Sevabertinib for HER2-Mutant Advanced NSCLC Patients  Oncology Nursing News

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 12, 2026.

By

Related Post

Regulatory Approvals

FDA approves Pharming’s Joenja for children

Regulatory Approvals

Scholar Rock wins FDA approval for ISEMBYLD, the first muscle-targeted treatment for spinal muscular atrophy

Regulatory Approvals

FDA Approves Apitegromab for Spinal Muscular Atrophy

Financial News For All

Litigation

DOJ sues Utah in wider push against in-state tuition for unauthorized immigrants

Litigation

The Simply Good Foods Company (SMPL) Class Action Lawsuit Seeks Recovery for Investors; October 13, 2026, Deadline – Contact Kessler Topaz Meltzer & Check, LLP

Litigation

Arizona AG files consumer fraud lawsuit against cosmetics company L’Oréal

Litigation

FTC Secures $12 Million Settlement Against Payment Processor for Facilitating Merchant Fraud